Choi Sunhyung, Park Bombi, Lee Eun-Gyeong, Lee Seeyoun, Kang Han-Sung, Jung So-Youn, Lee Dong-Eun, Han Jai-Hong
Department of Surgery, National Health Insurance Service Ilsan Hospital, Goyang, South Korea.
Department of Surgery, Center for Breast Cancer, National Cancer Center, Goyang, South Korea.
Breast Cancer Res Treat. 2025 Oct;213(3):325-334. doi: 10.1007/s10549-025-07768-6. Epub 2025 Aug 1.
Ductal carcinoma in situ (DCIS) is a non-invasive breast cancer with variable risk of upstaging to invasive carcinoma. Accurate preoperative risk stratification is critical to guide management decisions and minimize overtreatment. This study aimed to identify clinicopathological and imaging predictors of DCIS upstaging to invasive cancer.
We conducted a retrospective analysis of 701 patients diagnosed with DCIS, among whom 200 (28.5%) were upstaged to microinvasive or invasive carcinoma. Logistic regression was used to evaluate the association between upstaging and various factors, including tumor size, nuclear grade, comedo necrosis, progesterone receptor (PR) negativity, human epidermal growth factor receptor 2 (HER2) overexpression, and mammographic findings.
Tumor size > 5 cm, comedo necrosis, PR negativity, and mammographic microcalcifications were independent predictors of upstaging. While HER2 overexpression was significant in univariate analysis, it was not retained in the multivariate model. Non-mass lesions on ultrasound and magnetic resonance imaging (MRI) were not significant predictors.
Integrating these markers into preoperative risk stratification models may improve individualized treatment planning and reduce overtreatment in patients with DCIS.
导管原位癌(DCIS)是一种非浸润性乳腺癌,进展为浸润性癌的风险各异。准确的术前风险分层对于指导治疗决策和减少过度治疗至关重要。本研究旨在确定DCIS进展为浸润性癌的临床病理和影像学预测因素。
我们对701例诊断为DCIS的患者进行了回顾性分析,其中200例(28.5%)进展为微浸润或浸润性癌。采用逻辑回归评估进展与各种因素之间的关联,这些因素包括肿瘤大小、核分级、粉刺样坏死、孕激素受体(PR)阴性、人表皮生长因子受体2(HER2)过表达以及乳腺X线摄影表现。
肿瘤大小>5 cm、粉刺样坏死、PR阴性和乳腺X线摄影微钙化是进展的独立预测因素。虽然HER2过表达在单变量分析中具有显著性,但在多变量模型中未保留。超声和磁共振成像(MRI)上的非肿块性病变不是显著的预测因素。
将这些标志物纳入术前风险分层模型可能会改善DCIS患者的个体化治疗方案并减少过度治疗。